Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial)

Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial)

<p dir="ltr">Patients with coronavirus disease (COVID-19) commonly experience distressing and challenging respiratory symptoms. Interventions such as oxygen therapy, oral opiates, and traditional nebulizers like ipratropium bromide and salbutamol are variable in their efficacy, and t...

Full description

Saved in:
Bibliographic Details
Main Author: Nissar Shaikh (11659441) (author)
Other Authors: Mohamad Y. Khatib (11659459) (author), Mohammad A. Al Wraidat (21322907) (author), Ahmed S. Mohamed (11659456) (author), Anood A. Al-Assaf (21322910) (author), Abdul Gafoor M. Tharayil (21322913) (author), Ahmad A. Abujaber (14586054) (author), Abdulqadir J. Nashwan (11659453) (author)
Published: 2022
Subjects:
Biomedical and clinical sciences
Clinical sciences
Pharmacology and pharmaceutical sciences
Health sciences
Epidemiology
cough
COVID-19
dyspnea
nebulized fentanyl
normal saline 0.9%
throat pain
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items